Phage therapy: Awakening a sleeping giant

Emerging Topics in Life Sciences

Volumn 1, Issue 1, 2017, Pages 93-103

  Roach, Dwayne R ^a   Debarbieux, Laurent ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85021812964     PISSN: 23978554     EISSN: 23978562     Source Type: Journal    
DOI: 10.1042/ETLS20170002     Document Type: Review

References (105)

1. Costelloe, C., Metcalfe, C., Lovering, A., Mant, D. and Hay, A.D. (2010) Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: Systematic review and meta-analysis. Br. Med. J. 340, c2096 doi:10.1136/bmj.c2096
2. Van Boeckel, T.P., Gandra, S., Ashok, A., Caudron, Q., Grenfell, B.T., Levin, S.A. et al. (2014) Global antibiotic consumption 2000 to 2010: An analysis of national pharmaceutical sales data. Lancet Infect. Dis. 14, 742-750 doi:10.1016/S1473-3099(14)70780-7
3. CDC (2013) Antibiotic resistance threats in the United States. US Centers for Disease Control and Prevention. http://www.cdc.gov/drugresistance/threat-report-2013
4. Butler, M.S., Blaskovich, M.A.T. and Cooper, M.A. (2017) Antibiotics in the clinical pipeline at the end of 2015. J. Antibiot. 70, 3-24 doi:10.1038/ja. 2016.72
5. Czaplewski, L., Bax, R., Clokie, M., Dawson, M., Fairhead, H., Fischetti, V.A. et al. (2016) Alternatives to antibiotics - a pipeline portfolio review. Lancet Infect. Dis. 16, 239-251 doi:10.1016/S1473-3099(15)00466-1
6. Publications Service. (2007) On an invisible microbe antagonistic toward dysenteric bacilli: Brief note by Mr. F. D'Herelle, presented by Mr. Roux. Res. Microbiol. 158, 553-554 doi:10.1016/j.resmic.2007.07.005
7. Chanishvili, N. (2016) Bacteriophages as therapeutic and prophylactic means: Summary of the Soviet and post Soviet experiences. Cur. Drug Deliv. 13, 309-323 doi:10.2174/156720181303160520193946
8. Górski, A., Miȩdzybrodzki, R., Weber-Dabrowska, B., Fortuna, W., Letkiewicz, S., Rogóz, P. et al. (2016) Phage therapy: Combating infections with potential for evolving from merely a treatment for complications to targeting diseases. Front. Microbiol. 7, 1515 doi:10.3389/fmicb.2016.01515
9. McCarville, J.L., Caminero, A. and Verdu, E.F. (2016) Novel perspectives on therapeutic modulation of the gut microbiota. Ther. Adv. Gastroenterol. 9, 580-593 doi:10.1177/1756283X16637819
10. Keen, E.C. (2015) A century of phage research: Bacteriophages and the shaping of modern biology. BioEssays 37, 6-9 doi:10.1002/bies.201400152
11. Chevallereau, A., Blasdel, B.G., De Smet, J., Monot, M., Zimmermann, M., Kogadeeva, M. et al. (2016) Next-generation '-omics' approaches reveal a massive alteration of host RNA metabolism during bacteriophage infection of Pseudomonas aeruginosa. PLoS Genet. 12, e1006134 doi:10.1371/journal.pgen.1006134
12. Taylor, N.M.I., Prokhorov, N.S., Guerrero-Ferreira, R.C., Shneider, M.M., Browning, C., Goldie, K.N. et al. (2016) Structure of the T4 baseplate and its function in triggering sheath contraction. Nature 533, 346-352 doi:10.1038/nature17971
13. Pires, D.P., Cleto, S., Sillankorva, S., Azeredo, J. and Lu, T.K. (2016) Genetically engineered phages: A review of advances over the last decade. Microbiol. Mol. Biol. Rev. 80, 523-543 doi:10.1128/MMBR.00069-15
14. Ackermann, H.-W. and Prangishvili, D. (2012) Prokaryote viruses studied by electron microscopy. Arch. Virol. 157, 1843-1849 doi:10.1007/s00705-012-1383-y
15. Hatfull, G.F. and Hendrix, R.W. (2011) Bacteriophages and their genomes. Curr. Opin. Virol. 1, 298-303 doi:10.1016/j.coviro.2011.06.009
16. Oechslin, F., Piccardi, P., Mancini, S., Gabard, J., Moreillon, P., Entenza, J.M. et al. (2016) Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence. J. Infect. Dis. jiw632 doi:10.1093/infdis/jiw632
17. Ross, A., Ward, S. and Hyman, P. (2016) More is better: Selecting for broad host range bacteriophages. Front. Microbiol. 7, 1352 doi:10.3389/fmicb.2016.01352
18. Francino, M.P. (2015) Antibiotics and the human gut microbiome: Dysbioses and accumulation of resistances. Front. Microbiol. 6, 1543 doi:10.3389/fmicb.2015.01543
19. Sulakvelidze, A., Alavidze, Z. and Morris, Jr, J.G. (2001) Bacteriophage therapy. Antimicrob. Agents Chemother. 45, 649-659 doi:10.1128/AAC.45.3. 649-659.2001
20. Sarker, S.A. and Brüssow, H. (2016) From bench to bed and back again: Phage therapy of childhood Escherichia coli diarrhea. Ann. N.Y. Acad. Sci. 1372, 42-52 doi:10.1111/nyas.13087
21. Pantůcě k, R., Rosypalová, A., Doškar J., Kailerová, J., Růžick ová, V., Borecká, P. et al. (1998) The polyvalent staphylococcal phage w812: Its host-range mutants and related phages. Virology 246, 241-252 doi:10.1006/viro.1998.9203
22. Kerr, B., Neuhauser, C., Bohannan, B.J.M. and Dean, A.M. (2006) Local migration promotes competitive restraint in a host-pathogen 'tragedy of the commons'. Nature 442, 75-78 doi:10.1038/nature04864
23. Morgan, A.D., Gandon, S. and Buckling, A. (2005) The effect of migration on local adaptation in a coevolving host-parasite system. Nature 437, 253-256 doi:10.1038/nature03913
24. Betts, A., Kaltz, O. and Hochberg, M.E. (2014) Contrasted coevolutionary dynamics between a bacterial pathogen and its bacteriophages. Proc. Natl Acad. Sci. U.S.A. 111, 11109-11114 doi:10.1073/pnas.1406763111
25. Zgurskaya, H.I., López, C.A. and Gnanakaran, S. (2015) Permeability barrier of Gram-negative cell envelopes and approaches to bypass it. ACS Infect. Dis. 1, 512-522 doi:10.1021/acsinfecdis.5b00097
26. Lu, T.K. and Collins, J.J. (2007) Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl Acad. Sci. U.S.A. 104, 11197-11202 doi:10. 1073/pnas.0704624104
27. Lin, T.-Y., Lo, Y.-H., Tseng, P.-W., Chang, S.-F., Lin, Y.-T. and Chen, T.-S. (2012) A T3 and T7 recombinant phage acquires efficient adsorption and a broader host range. PLoS ONE 7, e30954 doi:10.1371/journal.pone.0030954
28. Staquicini, F.I., Ozawa, M.G., Moya, C.A., Driessen, W.H.P., Barbu, E.M., Nishimori, H. et al. (2011) Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J. Clin. Invest. 121, 161-173 doi:10.1172/JCI44798
29. Rangel, R., Guzman-Rojas, L., le Roux, L.G., Staquicini, F.I., Hosoya, H., Barbu, E.M. et al. (2012) Combinatorial targeting and discovery of ligand-receptors in organelles of mammalian cells. Nat. Commun. 3, 788 doi:10.1038/ncomms1773
30. Roach, D.R. and Donovan, D.M. (2015) Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage 5, e1062590 doi:10. 1080/21597081.2015.1062590
31. Nemeth, J., Oesch, G. and Kuster, S.P. (2015) Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: Systematic review and meta-analysis. J. Antimicrob. Chemother. 70, 382-395 doi:10.1093/jac/dku379
32. Hagens, S., Habel, A., von Ahsen, U., von Gabain, A. and Blasi, U. (2004) Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob. Agents Chemother. 48, 3817-3822 doi:10.1128/AAC.48.10.3817-3822.2004
33. Matsuda, T., Freeman, T.A., Hilbert, D.W., Duff, M., Fuortes, M., Stapleton, P.P. et al. (2005) Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery 137, 639-646 doi:10.1016/j.surg.2005.02.012
34. Pei, R. and Lamas-Samanamud, G.R. (2014) Inhibition of biofilm formation by T7 bacteriophages producing quorum-quenching enzymes. Appl. Environ. Microbiol. 80, 5340-5348 doi:10.1128/AEM.01434-14
35. Lu, T.K. and Collins, J.J. (2009) Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl Acad. Sci. U.S.A. 106, 4629-4634 doi:10.1073/pnas.0800442106
36. Edgar, R., Friedman, N., Molshanski-Mor, S. and Qimron, U. (2012) Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes. Appl. Environ. Microbiol. 78, 744-751 doi:10.1128/AEM.05741-11
37. Cumby, N., Davidson, A.R. and Maxwell, K.L. (2012) The moron comes of age. Bacteriophage 2, e23146 doi:10.4161/bact.23146
38. Krom, R.J., Bhargava, P., Lobritz, M.A. and Collins, J.J. (2015) Engineered phagemids for nonlytic, targeted antibacterial therapies. Nano Letters 15, 4808-4813 doi:10.1021/acs.nanolett.5b01943
39. Bikard, D., Euler, C.W., Jiang, W., Nussenzweig, P.M., Goldberg, G.W., Duportet, X. et al. (2014) Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat. Biotechnol. 32, 1146-1150 doi:10.1038/nbt.3043
40. Citorik, R.J., Mimee, M. and Lu, T.K. (2014) Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat. Biotechnol. 32, 1141-1145 doi:10.1038/nbt.3011
41. Yosef, I., Manor, M., Kiro, R. and Qimron, U. (2015) Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc. Natl Acad. Sci. U.S.A. 112, 7267-7272 doi:10.1073/pnas.1500107112
42. Cui, L. and Bikard, D. (2016) Consequences of Cas9 cleavage in the chromosome of Escherichia coli. Nucleic Acids Res. 44, 4243-4251 doi:10.1093/nar/gkw223
43. Reyes, A., Semenkovich, N.P., Whiteson, K., Rohwer, F. and Gordon, J.I. (2012) Going viral: next-generation sequencing applied to phage populations in the human gut. Nat. Rev. Microbiol. 10, 607-617 doi:10.1038/nrmicro2853
44. Fodor, A.R. and Adams, M.H. (1955) Genetic control of serological specificity in bacteriophage. J. Immunol. 74, 228-235 PMID:14354205
45. Peacock, D.B., Jones, J.V. and Gough, M. (1973) The immune response to φX 174 in man. I. Primary and secondary antibody production in normal adults. Clin. Exp. Immunol. 13, 497-513 PMID:4197826
46. Kamme, C. (1973) Antibodies against staphylococcal bacteriophages in human sera. I. Assay of antibodies in healthy individuals and in patients with staphylococcal infections. Acta Pathol. Microbiol. Scand. B Microbiol. Immunol. 81, 741-748 PMID:4273800
47. Smith, L.L., Buckley, R. and Lugar, P. (2014) Diagnostic immunization with bacteriophage φX 174 in patients with common variable immunodeficiency/hypogammaglobulinemia. Front. Immunol. 5, 410 doi:10.3389/fimmu.2014.00410
48. Dabrowska, K., Miernikiewicz, P., Piotrowicz, A., Hodyra, K., Owczarek, B., Lecion, D. et al. (2014) Immunogenicity studies of proteins forming the T4 phage head surface. J. Virol. 88, 12551-12557 doi:10.1128/JVI.02043-14
49. Łusiak-Szelachowska, M., Zaczek, M., Weber-Dabrowska, B., Miȩdzybrodzki, R., Kłak, M., Fortuna, W. et al. (2014) Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 27, 295-304 doi:10.1089/vim.2013.0128
50. Majewska, J., Beta, W., Lecion, D., Hodyra-Stefaniak, K., Kłopot, A., Kaźmierczak, Z. et al. (2015) Oral application of T4 phage induces weak antibody production in the gut and in the blood. Viruses 7, 4783-4799 doi:10.3390/v7082845
51. Capparelli, R., Parlato, M., Borriello, G., Salvatore, P. and Iannelli, D. (2007) Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob. Agents Chemother. 51, 2765-2773 doi:10.1128/AAC.01513-06
52. Bruttin, A. and Brussow, H. (2005) Human volunteers receiving Escherichia coli phage T4 orally: A safety test of phage therapy. Antimicrob. Agents Chemother. 49, 2874-2878 doi:10.1128/AAC.49.7.2874-2878.2005
53. Pincus, N.B., Reckhow, J.D., Saleem, D., Jammeh, M.L., Datta, S.K. and Myles, I.A. (2015) Strain specific phage treatment for Staphylococcus aureus infection is influenced by host immunity and site of infection. PLoS ONE 10, e0124280 doi:10.1371/journal.pone.0124280
54. Kim, K.-P., Cha, J.-D., Jang, E.-H., Klumpp, J., Hagens, S., Hardt, W.-D. et al. (2008) PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response. Microb. Biotechnol. 1, 247-257 doi:10.1111/j.1751-7915.2008.00028.x
55. Singla, S., Harjai, K., Katare, O.P. and Chhibber, S. (2016) Encapsulation of bacteriophage in liposome accentuates its entry in to macrophage and shields it from neutralizing antibodies. PLoS ONE 11, e0153777 doi:10.1371/journal.pone.0153777
56. Akira, S., Uematsu, S. and Takeuchi, O. (2006) Pathogen recognition and innate immunity. Cell 124, 783-801 doi:10.1016/j.cell.2006.02.015
57. Merril, C.R., Biswas, B., Carlton, R., Jensen, N.C., Creed, G.J., Zullo, S. et al. (1996) Long-circulating bacteriophage as antibacterial agents. Proc. Natl Acad. Sci. U.S.A. 93, 3188-3192 doi:10.1073/pnas.93.8.3188
58. Hodyra-Stefaniak, K., Miernikiewicz, P., Drapała, J., Drab, M., Jończyk-Matysiak, E., Lecion, D. et al. (2015) Mammalian host-versus-phage immune response determines phage fate in vivo. Sci. Rep. 5, 14802 doi:10.1038/srep14802
59. Barfoot, R., Denham, S., Gyure, L.A., Hall, J.G., Hobbs, S.M., Jackson, L.E. et al. (1989) Some properties of dendritic macrophages from peripheral lymph. Immunology 68, 233-239 PMID:2807381
60. Weber-Dabrowska, B., Zimecki, M., Mulczyk, M. and Górski, A. (2002) Effect of phage therapy on the turnover and function of peripheral neutrophils. FEMS Immunol. Med. Microbiol. 34, 135-138 doi:10.1111/j.1574-695X.2002.tb00614.x
61. Przerwa, A., Zimecki, M., Świtała-Jeleń, K., Dabrowska, K., Krawczyk, E., Łuczak, M. et al. (2006) Effects of bacteriophages on free radical production and phagocytic functions. Med. Microbiol. Immunol. 195, 143-150 doi:10.1007/s00430-006-0011-4
62. An, T.-W., Kim, S.-J., Lee, Y.-D., Park, J.-H. and Chang, H.-I. (2014) The immune-enhancing effect of the Cronobacter sakazakii ES2 phage results in the activation of nuclear factor-κB and dendritic cell maturation via the activation of IL-12p40 in the mouse bone marrow. Immunol. Lett. 157, 1-8 doi:10.1016/j.imlet.2013.10.007
63. Jończyk-Matysiak, E., Łusiak-Szelachowska, M., Kłak, M., Bubak, B., Miȩdzybrodzki, R., Weber-Dabrowska, B. et al. (2015) The effect of bacteriophage preparations on intracellular killing of bacteria by phagocytes. J. Immunol. Res. 2015, 1-13 doi:10.1155/2015/482863
64. Dufour, N., Henry, M., Ricard, J.-D. and Debarbieux, L. (2016) Commentary: Morphologically distinct Escherichia coli bacteriophages differ in their efficacy and ability to stimulate cytokine release in vitro. Front. Microbiol. 7, 1029 doi:10.3389/fmicb.2016.01029
65. Rhoads, D.D., Wolcott, R.D., Kuskowski, M.A., Wolcott, B.M., Ward, L.S. and Sulakvelidze, A. (2009) Bacteriophage therapy of venous leg ulcers in humans: Results of a phase I safety trial. J. Wound Care 18, 237-238, 240-243 doi:10.12968/jowc.2009.18.6.42801
66. Wright, A., Hawkins, C.H., Äanggård, E.E. and Harper, D.R. (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34, 349-357 doi:10.1111/j.1749-4486.2009.01973.x
67. Abedon, S.T. (2012) Bacterial 'immunity' against bacteriophages. Bacteriophage 2, 50-54 doi:10.4161/bact.18609
68. Bull, J.J., Vegge, C.S., Schmerer, M., Chaudhry, W.N. and Levin, B.R. (2014) Phenotypic resistance and the dynamics of bacterial escape from phage control. PLoS ONE 9, e94690 doi:10.1371/journal.pone.0094690
69. Labrie, S.J., Samson, J.E. and Moineau, S. (2010) Bacteriophage resistance mechanisms. Nat. Rev. Microbiol. 8, 317-327 doi:10.1038/nrmicro2315
70. León, M. and Bastías, R. (2015) Virulence reduction in bacteriophage resistant bacteria. Front. Microbiol. 6, 343 doi:10.3389/fmicb.2015.00343
71. Roach, D.R., Sjaarda, D.R., Castle, A.J. and Svircev, A.M. (2013) Host exopolysaccharide quantity and composition impact Erwinia amylovora bacteriophage pathogenesis. Appl. Environ. Microbiol. 79, 3249-3256 doi:10.1128/AEM.00067-13
72. Gomez, P. and Buckling, A. (2011) Bacteria-phage antagonistic coevolution in soil. Science 332, 106-109 doi:10.1126/science.1198767
73. Filippov, A.A., Sergueev, K.V., He, Y., Huang, X.-Z., Gnade, B.T., Mueller, A.J. et al. (2011) Bacteriophage-resistant mutants in Yersinia pestis: Identification of phage receptors and attenuation for mice. PLoS ONE 6, e25486 doi:10.1371/journal.pone.0025486
74. Taneja, N. and Kaur, H. (2016) Insights into newer antimicrobial agents against Gram-negative bacteria. Microbiol. Insights 9, 9-19 doi:10.4137/MBI.S29459
75. Le, S., Yao, X., Lu, S., Tan, Y., Rao, X., Li, M. et al. (2014) Chromosomal DNA deletion confers phage resistance to Pseudomonas aeruginosa. Sci. Rep. 4, 4738 doi:10.1038/srep04738
76. Chan, B.K., Sistrom, M., Wertz, J.E., Kortright, K.E., Narayan, D. and Turner, P.E. (2016) Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 6, 26717 doi:10.1038/srep26717
77. Palmer, K.L. and Gilmore, M.S. (2010) Multidrug-resistant enterococci lack CRISPR-cas. mBio 1, e00227-10 doi:10.1128/mBio.00227-10
78. Meyer, J.R., Agrawal, A.A., Quick, R.T., Dobias, D.T., Schneider, D. and Lenski, R.E. (2010) Parallel changes in host resistance to viral infection during 45, 000 generations of relaxed selection. Evolution 64, 3024-3034 doi:10.1111/j.1558-5646.2010.01049.x
79. Samson, J.E., Magadán, A.H., Sabri, M. and Moineau, S. (2013) Revenge of the phages: Defeating bacterial defences. Nat. Rev. Microbiol. 11, 675-687 doi:10.1038/nrmicro3096
80. Krüger, D.H. and Bickle, T.A. (1983) Bacteriophage survival: Multiple mechanisms for avoiding the deoxyribonucleic acid restriction systems of their hosts. Microbiol. Rev. 47, 345-360 PMID:6314109
81. Pawluk, A., Amrani, N., Zhang, Y., Garcia, B., Hidalgo-Reyes, Y., Lee, J. et al. (2016) Naturally occurring off-switches for CRISPR-Cas9. Cell 167, 1829-1838.e9 doi:10.1016/j.cell.2016.11.017
82. Johnson, P.J.T. and Levin, B.R. (2013) Pharmacodynamics, population dynamics, and the evolution of persistence in Staphylococcus aureus. PLoS Genet 9, e1003123 doi:10.1371/journal.pgen.1003123
83. Levin, B.R., Moineau, S., Bushman, M. and Barrangou, R. (2013) The population and evolutionary dynamics of phage and bacteria with CRISPR-mediated immunity. PLoS Genet. 9, e1003312 doi:10.1371/journal.pgen.1003312
84. Brussow, H. (2012) What is needed for phage therapy to become a reality in Western medicine? Virology 434, 138-142 doi:10.1016/j.virol.2012.09.015
85. Debarbieux, L., Pirnay, J.-P., Verbeken, G., De Vos, D., Merabishvili, M., Huys, I. et al. (2016) A bacteriophage journey at the European Medicines Agency. FEMS Microbiol. Lett. 363, fnv225 doi:10.1093/femsle/fnv225
86. Fauconnier, A. (2017) Regulating phage therapy: The biological master file concept could help to overcome regulatory challenge of personalized medicines. EMBO Rep. 18, 198-200 doi:10.15252/embr.201643250
87. Jordan, T.C., Burnett, S.H., Carson, S., Caruso, S.M., Clase, K., DeJong, R.J. et al. (2014) A broadly implementable research course in phage discovery and genomics for first-year undergraduate students. mBio 5, e01051-13 doi:10.1128/mBio.01051-13
88. Nwokoro, E., Leach, R., Årdal, C., Baraldi, E., Ryan, K. and Plahte, J. (2016) An assessment of the future impact of alternative technologies on antibiotics markets. J. Pharma Policy Pract. 9, 34 doi:10.1186/s40545-016-0085-3
89. Gubala, V., Harris, L.F., Ricco, A.J., Tan, M.X. and Williams, D.E. (2012) Point of care diagnostics: Status and future. Anal. Chem. 84, 487-515 doi:10.1021/ac2030199
90. Chan, B.K. and Abedon, S.T. (2012) Phage therapy pharmacology phage cocktails. Adv. Appl. Microbiol. 78, 1-23 doi:10.1016/B978-0-12-394805-2. 00001-4
91. Pirnay, J.-P., Blasdel, B.G., Bretaudeau, L., Buckling, A., Chanishvili, N., Clark, J.R. et al. (2015) Quality and safety requirements for sustainable phage therapy products. Pharma Res. 32, 2173-2179 doi:10.1007/s11095-014-1617-7
92. Cooper, C.J., Khan Mirzaei, M. and Nilsson, A.S. (2016) Adapting drug approval pathways for bacteriophage-based therapeutics. Front. Microbiol. 7, 1209 doi:10.3389/fmicb.2016.01209
93. Kusradze, I., Karumidze, N., Rigvava, S., Dvalidze, T., Katsitadze, M., Amiranashvili, I. et al. (2016) Characterization and testing the efficiency of Acinetobacter baumannii phage vB-GEC_Ab-M-G7 as an antibacterial agent. Front. Microbiol. 7, 1590 doi:10.3389/fmicb.2016.01590
94. Mai, V., Ukhanova, M., Reinhard, M.K., Li, M. and Sulakvelidze, A. (2015) Bacteriophage administration significantly reduces Shigella colonization and shedding by Shigella-challenged mice without deleterious side effects and distortions in the gut microbiota. Bacteriophage 5, e1088124 doi:10.1080/21597081.2015.1088124
95. Pouillot, F., Chomton, M., Blois, H., Courroux, C., Noelig, J., Bidet, P. et al. (2012) Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob. Agents Chemother. 56, 3568-3575 doi:10.1128/AAC.06330-11
96. Kishor, C., Mishra, R.R., Saraf, S.K., Kumar, M., Srivastav, A.K. and Nath, G. (2016) Phage therapy of staphylococcal chronic osteomyelitis in experimental animal model. Indian J. Med. Res. 143, 87-94 doi:10.4103/0971-5916.178615
97. Hawkins, C., Harper, D., Burch, D., Äanggård, E. and Soothill, J. (2010) Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: A before/after clinical trial. Vet. Microbiol. 146, 309-313 doi:10.1016/j.vetmic.2010.05.014
98. Westwater, C., Kasman, L.M., Schofield, D.A., Werner, P.A., Dolan, J.W., Schmidt, M.G. et al. (2003) Use of genetically engineered phage to deliver antimicrobial agents to bacteria: An alternative therapy for treatment of bacterial infections. Antimicrob. Agents Chemother. 47, 1301-1307 doi:10.1128/AAC.47.4.1301-1307.2003
99. Paul, V.D., Sundarrajan, S., Rajagopalan, S.S., Hariharan, S., Kempashanaiah, N., Padmanabhan, S. et al. (2011) Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection. BMC Microbiol. 11, 195 doi:10.1186/1471-2180-11-195
100. Shivshetty, N., Hosamani, R., Ahmed, L., Oli, A.K., Sannauallah, S., Sharanbassappa, S. et al. (2014) Experimental protection of diabetic mice against lethal P. aeruginosa infection by bacteriophage. BioMed Res. Int. 2014, 1-11 doi:10.1155/2014/793242
101. Henry, M., Lavigne, R. and Debarbieux, L. (2013) Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob. Agents Chemother. 57, 5961-5968 doi:10.1128/AAC.01596-13
102. Pabary, R., Singh, C., Morales, S., Bush, A., Alshafi, K., Bilton, D. et al. (2016) Antipseudomonal bacteriophage reduces infective burden and inflammatory response in murine lung. Antimicrob. Agents Chemother. 60, 744-751 doi:10.1128/AAC.01426-15
103. Dufour, N., Debarbieux, L., Fromentin, M. and Ricard, J.-D. (2015) Treatment of highly virulent extraintestinal pathogenic Escherichia coli pneumonia with bacteriophages. Crit. Care Med. 43, e190-e198 doi:10.1097/CCM.0000000000000968
104. Singla, S., Harjai, K., Katare, O.P. and Chhibber, S. (2015) Bacteriophage-loaded nanostructured lipid carrier: Improved pharmacokinetics mediates effective resolution of Klebsiella pneumoniae-induced lobar pneumonia. J. Infect. Dis. 212, 325-334 doi:10.1093/infdis/jiv029
105. Chadha, P., Katare, O.P. and Chhibber, S. (2016) In vivo efficacy of single phage versus phage cocktail in resolving burn wound infection in BALB/c mice. Microb. Pathog. 99, 68-77 doi:10.1016/j.micpath.2016.08.001